Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic

Lei Lei Wu

News Reporter

While Gilead dropped disappointing data on its Arcus-partnered CD37 inhibitor Wednesday afternoon, the biopharma is making moves to cushion its immune checkpoint pipeline. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Look­ing to bol­ster im­mune check­point R&D, Gilead buys Miro­Bio as it takes next-gen check­point ther­a­py to the clin­ic

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic